Candida Glabrata

Finding Candida glabrata in stool usually reflects carriage, and carriage alone doesn't establish a yeast infection. This species can cause serious disease when your immune defenses are weakened or your intestinal barrier is damaged. Whether measuring its abundance in stool helps predict or prevent that disease remains unproven.

This test uses PCR to detect the yeast's DNA in a stool sample. PCR makes copies of selected DNA sequences so they can be detected and quantified. The catalog reports the result in CFU/g stool. That unit conventionally describes colonies grown from a gram of stool, but this PCR result is a DNA-based abundance estimate rather than a direct count of living yeast. The laboratory's calibration determines how the DNA signal is expressed in those units.

For assessing gut health or predicting infection, this is an exploratory marker. There are no validated disease-risk cutoffs or treatment targets for this specific measurement. Detecting DNA accurately and showing that a result improves a medical decision are separate questions.

A Yeast That Can Live Harmlessly in the Gut

Candida glabrata can live in the gut, mouth, and vagina without causing disease. Its newer scientific name is Nakaseomyces glabratus. The balance between harmless carriage and infection depends on your immune system, the integrity of tissue barriers, other microbes, and the strain involved.

A stool sample captures material leaving the intestine. Detecting fungal DNA there doesn't establish that the organism is alive, permanently settled in the gut, or invading the intestinal lining. Studies of gut fungi also show that organisms passing through from food or the mouth can contribute to stool findings. That is a general limitation of stool fungal analysis, not proof that any particular C. glabrata result comes from those sources.

Gut Carriage and Invasive Infection

The intestine can be a source of invasive Candida infection in people with severe immune suppression. In a small study of donor stem cell transplant recipients, researchers matched fungal strains in stool and blood and observed intestinal expansion before bloodstream infection. Members of the C. parapsilosis group caused most of the bloodstream infections in that cohort, where patients received echinocandin prophylaxis, and strain matching was shown for that group and for C. albicans. The study used sequencing and cultures, so it supports the biological possibility of spread from the gut but doesn't validate this C. glabrata stool PCR test.

A retrospective study of 475 people hospitalized in blood-cancer departments compared those with a heavy Candida burden in stool with those who had little or none. Heavy carriage was associated with higher one-year mortality. Bloodstream infections were also numerically more frequent, but that difference wasn't statistically conclusive. The heavily colonized group had more severe immune suppression and recent antibiotic exposure. This was a study of Candida collectively, not a species-specific PCR measurement, and it cannot establish a C. glabrata PCR threshold or show that reducing the stool result improves survival.

C. glabrata is an important bloodstream pathogen. In a database covering 13,177 candidemia-associated hospitalizations at participating US hospitals from 2016 through 2024, it surpassed C. albicans in the final year. The hospitals were a convenience sample, so this finding doesn't establish its rank in every region or hospital. These were blood-culture findings, not evidence that a positive stool result predicts bloodstream infection.

Invasive candidiasis is investigated with blood cultures and samples from the affected body site, sometimes alongside imaging or tissue examination. Blood cultures can miss deep tissue infection. Blood-based fungal markers and molecular tests can add information in selected settings, but none makes a stool result diagnostic of invasive disease.

What the Resistance Research Shows

C. glabrata is generally less susceptible to fluconazole than C. albicans, although individual strains differ. Fluconazole can be given by mouth or intravenously. Some strains also resist echinocandins, intravenous antifungal medicines commonly used first for bloodstream infection. Identifying the species raises a concern about resistance; determining whether a particular strain is resistant requires separate testing.

A Texas conference abstract reported C. glabrata in about 9% of 1,241 stool samples from hospitalized people with C. difficile infection. The investigators cultured the stool and tested recovered yeast against antifungal drugs. They reported about 70% of the C. glabrata isolates as resistant to caspofungin. That is a finding from a selected hospital population and a conference report, not an estimate of resistance in everyone carrying this yeast.

Caspofungin susceptibility testing also has documented variation between laboratories that can misclassify susceptible isolates as resistant. This limits how broadly that unusually high percentage can be applied. The stool PCR described here doesn't test antifungal susceptibility, regardless of how much DNA it detects.

Inflammatory Bowel Disease and Other Associations

Studies have linked changes in gut fungi with several diseases, but their findings use different specimens and methods. A larger share of fungal sequencing reads also needn't mean a larger absolute yeast population: the share can increase when other fungi decrease.

• Crohn's disease: a study of intestinal lining samples found C. glabrata overrepresented compared with healthy controls. Those tissue-associated findings aren't interchangeable with stool PCR. A separate stool PCR study of 91 people with inflammatory bowel disease, irritable bowel syndrome, or neither condition found C. glabrata in only a few participants and didn't establish it as a marker of bowel inflammation.
• Advanced HIV: a small Argentine study using stool fungal sequencing found altered fungal communities in severely immune-suppressed people with HIV, including enrichment of this species. It didn't establish a stool PCR level that predicts infection.
• Gallbladder removal and H. pylori: separate stool sequencing studies found a greater relative abundance of C. glabrata after gallbladder removal and among people with H. pylori infection. These comparisons don't show that the yeast caused symptoms or that treating it would help.
• Lupus: a study found changes in the stool fungal community and cultured C. glabrata from a selected sample. That doesn't establish a consistent species-specific increase or a useful test for lupus.

Research in recurrent C. difficile infection has also linked fungal community patterns with the success of fecal microbiota transplantation. The strongest species-specific findings concerned C. albicans, including experiments in mice. They don't establish that this C. glabrata PCR result predicts treatment success.

These studies support investigating fungi as part of the gut ecosystem. They don't make a positive result a diagnosis of an unhealthy gut or identify the cause of your symptoms.

When Results Can Be Misleading

• DNA can remain after cells die: standard PCR doesn't distinguish living yeast from residual DNA. A positive result after treatment doesn't by itself establish treatment failure.
• Extraction and amplification affect the estimate: methods differ in how effectively they release fungal DNA. Substances in stool can interfere with PCR, while contamination can introduce a signal.
• CFU/g doesn't make PCR equivalent to culture: culture measures yeast that grows under the chosen conditions. PCR estimates DNA abundance. Their numbers aren't interchangeable, and different PCR laboratories can use different targets and calibrations.
• Recent medicines change the context: antibiotics and antifungals can alter fungal communities or select different strains. A change after medication doesn't establish a change in symptoms, tissue damage, or infection risk.
• Collection and storage matter: contamination with urine or toilet water, inadequate sampling, or storage outside the laboratory's instructions can compromise the result.
• A negative stool result has limited scope: it means the target wasn't detected at the assay's detection limit in that sample. It doesn't exclude infection at another body site.

What Changes Over Time Mean

Repeated measurements may document changes in the DNA detected in stool, but the size of change that matters medically hasn't been established. A rising result doesn't prove that invasion is approaching, and a falling result doesn't establish recovery from a disease. Using the same laboratory reduces one source of variation without resolving those limits.